Goldman Sachs Group Reiterates “€143.00” Price Target for Safran (EPA:SAF)

Share on StockTwits

Goldman Sachs Group set a €143.00 ($166.28) price target on Safran (EPA:SAF) in a research report report published on Monday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Several other brokerages have also recently commented on SAF. Deutsche Bank reiterated a hold rating on shares of AIB Group in a report on Monday, April 8th. JPMorgan Chase & Co. reiterated a buy rating on shares of Intel in a report on Tuesday, June 11th. Credit Suisse Group set a €100.00 ($116.28) target price on shares of Safran and gave the stock a sell rating in a report on Friday, May 31st. UBS Group started coverage on shares of Chewy in a report on Tuesday, July 9th. They issued a buy rating and a $42.00 target price for the company. Finally, Berenberg Bank reiterated a buy rating and issued a GBX 220 ($2.87) target price on shares of Barclays in a report on Monday, April 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Safran presently has an average rating of Hold and a consensus price target of €128.80 ($149.77).

Shares of SAF opened at €129.95 ($151.10) on Monday. Safran has a one year low of €67.17 ($78.10) and a one year high of €92.36 ($107.40). The stock has a 50-day moving average price of €126.81.

Safran Company Profile

Safran SA, together with its subsidiaries, engages in the aerospace and defense businesses worldwide. The company operates through three segments: Aerospace Propulsion, Aircraft Equipment, and Defense. The Aerospace Propulsion segment designs, develops, produces, and markets propulsion systems for commercial aircraft, military transport, training and combat aircraft, rocket engines, civil and military helicopters, and tactical missiles and drones.

Further Reading: Bid-Ask Spread

Analyst Recommendations for Safran (EPA:SAF)

Receive News & Ratings for Safran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Safran and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.